Investigation of Tear Biomarkers as an Indicator of Human Health by Morton, Stephen et al.
Pilot 
Study  Objectives?
Investigation of Tear Biomarkers as an Indicator of Human Health
Abstract
ID Tear Biomarkers
Associated with clinically 
Diagnosed medical conditions
Investigate 
Study Design 
Analysis techniques
Analysis
Tear
Biomarkers
Ocular 
Health
Neurological 
Diseases
Study 
Design
Methods For 
Knowledge Production
Understand the medical conditions 
Where tear biomarker  knowledge is applied
Literature and Dialogue Survey The
State of Knowledge
on Tears
To see  how if knowledge 
about tear biomarkers can be used to
assess human health prior to, during, and after
exposure to microgravity
How is knowledge
About tears being used in clinical and 
Research Practice
https://ntrs.nasa.gov/search.jsp?R=20170005634 2019-08-31T07:07:38+00:00Z
A Pilot Study on the Investigation of Tear Biomarkers as an Indicator of Human Health   
Abstract 
     Scientific literature suggests that tear biomarkers can be used as a guide towards clinical 
diagnosis of human health (Hagan et al., 2016). This study will investigate whether tear 
biomarkers represents a research and clinical opportunity to assess human health prior to, during, 
and after exposure to the spaceflight environment.  The focus of this study is to compare 
biomarkers previously identified as potentially relevant to both ocular and brain health against 
unique physiological outcomes of exposure to the space flight environment.  
     Study subjects suffering from terrestrial conditions thought to be similar to Spaceflight 
Associated Neuro-ocular Syndrome (SANS: formerly VIIP), e.g. patients with idiopathic 
intracranial hypertension (IIH) and optic neuritis may be relevant to conditions associated with 
spaceflight. This study will review methodologies, tear biomarkers related to state of ocular and 
brain health, the strengths and weakness of using tear fluid biomarkers versus other body fluid 
samples, and will survey current  tear fluid biomarker knowledge in research and clinical 
practice. 
     A strength of using tear biomarkers is that sampling is non-invasive and used as a guide in 
understanding pathologies, including ocular and systemic inflammatory conditions (Cocho et al., 
2016)., Salvisberg et al., 2014).  Moreover, tear biomarkers may reflect diseases affecting the 
central nervous system (CNS) (Salvisberg et al., 2014). For example, in multiple sclerosis (MS) , 
the concordance rate between tear biomarkers versus cerebrospinal fluid (CSF) is approximately 
83%, indicating  that, in the majority of cases, tears are at least as effective as CSF in potentially 
identifying novel MS biomarkers (Devos et al., 2001).   
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